Dr Reddys Laboratories Ltd Analyst Rating
based on 37 analysts
26.32%
Buy
28.95%
Hold
44.74%
Sell
Based on 37 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹6700.7
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Share analysis
Dr Reddys Laboratories Ltd price forecast by 37 analysts
Downside of
High
₹8565
Target
₹6700.70
Low
₹5518
Dr Reddys Laboratories Ltd target price ₹6700.7, a slight downside of -0.6% compared to current price of ₹6697.4. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddys Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.62%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddys Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:6.58%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Performance
Day's Low
Day's High
₹6,686.05₹6,77052 Week's Low
52 Week's High
₹5,205.55₹7,107.45
| Returns % | |
| 1 Month Return | + 1.3 % |
| 3 Month Return | -0.44 % |
| 1 Year Return | + 21.42 % |
| Market Stats | |
| Previous Close | ₹6,741.10 |
| Open | ₹6,770.00 |
| Volume | 2.35L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,12,493.42Cr |
Dr Reddys Laboratories Ltd Key Statistics
| P/E Ratio | 20.16 |
| PEG Ratio | 0.4 |
| Market Cap | ₹1,12,493.42 Cr |
| P/B Ratio | 4.22 |
| EPS | 334.41 |
| Dividend Yield | 0.65 |
| Sector | Pharmaceuticals |
| ROE | 19.42 |
Dr Reddys Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,12,493.42 Cr | 27.97% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,59,871.82 Cr | 49.18% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,16,741.51 Cr | 62.62% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹40,814.40 Cr | 6.46% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹27,185.68 Cr | -1.86% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Dr Reddys Laboratories Ltd Mutual Fund Holdings
About Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹6697.40 per share as on 21 Oct, 2024 04:01 PM
Market Capitalisation: ₹1,12,493.42Cr as of today
Revenue: ₹7,672.70Cr as on June 2024 (Q2 24)
Net Profit: ₹1,392.40Cr as on June 2024 (Q2 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Dr Reddys Laboratories Ltd
Dr Reddy's Announces Stock Split and Dividend - 16 Oct, 2024
Dr Reddy's Laboratories will execute a 5:1 stock split and has declared a dividend of Rs 40 per share, effective October 28, 2024. The stock has shown positive performance, gaining 10.87% in six months and 15.30% year-to-date.
Hyderabad's Pharma Industry Strengthens Global Position - 13 Oct, 2024
Hyderabad, known as the Pharma Capital of India, significantly contributes to drug production, with Telangana producing over 40% of India's medicines, benefiting both domestic and international markets.
Dr Reddy's Announces Stock Split and F&O Adjustments - 12 Oct, 2024
Dr Reddy's Laboratories has announced a 5:1 stock split effective October 28, 2024. This will lead to adjustments in futures and options contracts, with strike prices and contract sizes modified accordingly. The overall trend of the stock is not expected to be impacted.
Dr Reddy's Approves Subsidiary Liquidation - 11 Oct, 2024
Dr Reddy's Laboratories shareholders have approved the voluntary liquidation of its subsidiary, Imperial Owners and Land Possessions, which is not material to the company's finances.
Dr Reddy's Subsidiary Advances CAR-T Cell Therapy - 09 Oct, 2024
Dr Reddy's Laboratories subsidiary, Aurigene Oncology, reported Phase 1 results for ibrecabtagene autoleucel (DRL-1801) from the SWASTH study, with Phase 2 trial approval granted.
Dr. Reddy's Advances CAR-T Therapy for Myeloma - 08 Oct, 2024
Dr. Reddy's subsidiary Aurigene Oncology announced promising Phase 1 results for Ribrecabtagene autoleucel, leading to DCGI approval for Phase 2 trials. All patients showed clinical response, with no serious side effects reported.
Dr. Reddy's Laboratories Announces Stock Split - 06 Oct, 2024
Dr. Reddy's Laboratories will split its shares into five parts, with a record date set for October 28, 2024. This marks the company's first stock split in 25 years. Despite a recent decline in share price, the company reported strong Q1FY25 performance.
Dr Reddys Partners with Gilead for Lenacapavir - 03 Oct, 2024
Dr Reddys Laboratories has entered a royalty-free licensing agreement with Gilead Sciences for the manufacture and commercialization of Lenacapavir in India and 120 other countries, boosting investor confidence.
Dr Reddys Partners with Gilead for HIV Drug - 02 Oct, 2024
Dr Reddys Laboratories has signed a royalty-free, non-exclusive licensing agreement with Gilead Sciences to manufacture and commercialize Lenacapavir, an HIV treatment, in India and 120 low- and middle-income countries.
Dr Reddy’s Gains Positive EMA Opinion for Biosimilar - 01 Oct, 2024
Dr Reddy’s Laboratories announced a positive opinion from the European Medicines Agency for its Rituximab biosimilar candidate, enhancing its market prospects in Europe.
Dr Reddy's Acquires Haleon's NRT Portfolio - 30 Sep, 2024
Dr Reddy's Laboratories has completed the acquisition of Haleon's global Nicotine Replacement Therapy portfolio for GBP 458 million, enhancing its consumer healthcare presence.
Dr. Reddy’s Invests in Nicotinell Acquisition - 28 Sep, 2024
Dr. Reddy’s Laboratories has invested $620 million in its Swiss subsidiary to acquire Haleon’s Nicotinell portfolio, a leader in nicotine replacement therapy. The acquisition includes various product formats and is expected to close in early Q4 2024, pending regulatory approvals.
Dr Reddy's Investment and Regulatory Fine Announced - 27 Sep, 2024
Dr Reddy's Laboratories faced a Rs 28 lakh fine in Mexico for regulatory issues while completing a $620 million investment in its Swiss subsidiary for acquiring the Nicotinell brand.
Dr. Reddy's Fined by Mexican Drug Regulator - 26 Sep, 2024
Dr. Reddy's Laboratories has been penalized ₹28 lakh by Mexico's COFEPRIS for failing to notify the import of a reference standard in advance. Despite this, shares rose by 0.39% on the BSE.
Nestle India Forms Joint Venture with Dr Reddy's - 24 Sep, 2024
Nestle India announced a joint venture with Dr Reddy's Laboratories to enhance their nutraceuticals portfolios in India, with equity shares split 49:51. This collaboration aims to combine Nestlé Health Science's nutritional solutions with Dr Reddy's established commercial strengths.
USFDA Inspection at Dr. Reddy's R&D Centre Successful - 23 Sep, 2024
Dr. Reddy's Laboratories announced that the USFDA completed a routine GMP inspection at its Bachupally R&D Centre with zero observations, indicating compliance with manufacturing standards.
Dr. Reddy's R&D Passes FDA Inspection Successfully - 20 Sep, 2024
Dr. Reddy's Laboratories' R&D center in Hyderabad successfully completed a US FDA inspection with zero observations. The stock is currently trading at Rs 6,551.15, with a target price of Rs 6,700.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, DRREDDY stock has moved up by 1.2%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 7.96% to 10.05% in Jun 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 7.31K Cr → 7.88K Cr (in ₹), with an average increase of 7.3% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.30K Cr → 1.39K Cr (in ₹), with an average increase of 5.9% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.65% of holdings in Jun 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 83.8% return, outperforming this stock by 62.3%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 133.4% return, outperforming this stock by 88.5%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 10.38% to 10.19% in Jun 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 29.14% to 27.68% in Jun 2024 quarter
News
Eicher Motors jumps 3% to hit lifetime high, stock price crosses ₹5,000 mark
Eicher Motors has been on a year-long gaining spree, rallying 48.63% during the period. The stock is up over 35% in the last 6 months.26 Jul, 2024 05:12 PMTrade Spotlight: How should you trade Eicher Motors, Info Edge, Mahanagar Gas, Snowman Logistics, and others on Monday?
Apollo Hospitals Enterprise, One 97 Communications (Paytm), Piramal Enterprises,Campus Activewear,IDFC First Bank, and Quess Corp will be in focus on Monday.28 Jul, 2024 11:35 AMEicher Motors Share Price Live Updates: Eicher Motors Closes at Rs 5012.50 with 6-Month Beta of 1.401
Join us on the Eicher Motors Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in the know with the latest information about Eicher Motors, including: Last traded price 5034.0, Market capitalization: 137347.77, Volume: 656, Price-to-earnings ratio 34.33, Earnings per share 146.02. Our liveblog provides a well-rounded view of Eicher Motors by incorporating both fundamental and technical indicators. Be the first to receive breaking news that can impact Eicher Motors's performance in the market. Our expert analysis and recommendations empower you to make informed investment choices. Stay informed and stay ahead with the Eicher Motors Stock Liveblog. The data points are updated as on 29-07-2024 09:12 IST29 Jul, 2024 08:32 AMDr Reddys Laboratories Ltd Financials
Index Inclusions
Dr Reddys Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.65% | ||
| Foreign Institutions | 27.68% | ||
| Mutual Funds | 10.05% | 26.33 | |
| Retail Investors | 10.19% | ||
| Others | 25.43% |
Dr Reddys Laboratories Ltd Key Indicators
Dr Reddys Laboratories Ltd Valuation
Dr Reddys Laboratories Ltd in the last 5 years
Lowest (15.84x)
October 7, 2019
Today (20.16x)
October 18, 2024
Industry (58.10x)
October 18, 2024
Highest (53.88x)
December 18, 2020
Dr Reddys Laboratories Ltd Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit fell -0.9% since last year same period to ₹1,392.40Cr in the Q1 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 6.31% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 1.19%.
Read More about Dividends
Dr Reddys Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Dr Reddys Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Reddys Laboratories Ltd shares.
Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹6697.4
Dr Reddys Laboratories Ltd is listed on NSE
Dr Reddys Laboratories Ltd is listed on BSE
- Today’s highest price of Dr Reddys Laboratories Ltd is ₹6770.
- Today’s lowest price of Dr Reddys Laboratories Ltd is ₹6686.05.
PE Ratio of Dr Reddys Laboratories Ltd is 20.16
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share
Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 2.35L.
Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹112493.42Cr.
| Dr Reddys Laboratories Ltd(DRREDDY | Price |
|---|---|
52 Week High | ₹7107.45 |
52 Week Low | ₹5205.55 |
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹6697.4. It is down -5.77% from its 52 Week High price of ₹7107.45
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹6697.4. It is up 28.66% from its 52 Week Low price of ₹5205.55
| Dr Reddys Laboratories Ltd(DRREDDY | Returns |
|---|---|
1 Day Returns | -43.7% |
1 Month Returns | 1.3% |
3 Month Returns | -0.44% |
1 Year Returns | 21.42% |